Abstract
To control and prevent the spread of COVID-19, generalized social distancing measures, such as traffic control and travel restriction acted in China. Previous studies indicated that the traffic conditions had significant influence on the air quality, and which was related to the respiratory diseases. This study aimed to reveal the nexus of travel restriction, air pollution and COVID-19. Shenzhen, one of the top 4 megacities in China was considered as the study area, statistical analysis methods, including linear/nonlinear regression and bivariate correlation was conducted to evaluate the relationship of the traffic and passenger population, travel intensity, NO2, PM10, PM2.5 and the number of COVID-19 confirmed cases. The results suggested that traffic control and travel restriction had a significant correlation with the number of COVID-19 confirmed cases, which shown negative correlation with the traffic intensity of the city, NO2, PM10 and PM2.5 show significant positive correlation with the traffic intensity, traffic control and travel restriction would slow down and prevent the spread of the viruses at the outbreak period. Different study scale might results in different results, thus the research focused on the nexus of traffic control and travel restriction, air pollution and COVID-19 should been enhanced in future, and differentiated epidemic control and prevention measures should be considered according to the different situation of cities as well as countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received no external funding.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.